Objective: This study aimed to evaluate the initial clinical outcomes of and patient satisfaction with the newly introduced extended monofocal Evolux™ intraocular lens following cataract surgery. Methods: A retrospective study was conducted, involving 18 patients (36 eyes) who received Evolux™ lenses bilaterally. The inclusion criteria comprised individuals over 40 years old with no active eye diseases, excluding cataracts, and no postoperative complications. Various parameters were evaluated, including distance, intermediate, and near visual acuity; refraction; defocus curves; dependency on spectacles; and patient satisfaction. Patient satisfaction and visual quality of life were measured using the Catquest-9SF and QOV questionnaires. Results: The average age of the patients was 72.7 years, with the majority being women (77.8%). The results demonstrated excellent postoperative visual acuity at different distances. The mean logMAR values for uncorrected visual acuity were −0.04 for distance vision, 0.15 for intermediate vision, and 0.35 for near vision. The defocus curve indicated good tolerance, with visual acuity exceeding 20/20 in significant defocus ranges. Most patients expressed high satisfaction with their vision without spectacles, particularly for distance and intermediate vision. The need for spectacles for near vision was notably reduced. Furthermore, there was a low incidence of photic phenomena like halos and glare, contributing to the overall high patient satisfaction. Conclusions: Evolux™ lenses were found to be an effective choice for cataract surgery, providing excellent visual acuity at various distances and high patient satisfaction.

Background/Objectives: To evaluate the clinical and patient-reported outcomes (PROMs) obtained with an optimized version of a previously investigated trifocal IOL. Methods: Prospective non-comparative single-center study enrolling 29 patients (55–71 years) undergoing bilateral cataract surgery with implantation of the trifocal diffractive IOL Liberty 677CMY (Medicontur Medical Engineering Ltd., Zsámbék, Hungary). Visual and refractive outcomes as well as PROMs were evaluated during a 3-month follow-up: measurement of uncorrected and corrected distance (UDVA, CDVA), intermediate (UIVA, DCIVA) and near visual acuities (UNVA, DCNVA), defocus curve, patient satisfaction, photic phenomena perception, spectacle independence, and difficulty in performing some vision-related activities. Results: A total of 100%, 92%, and 80% of patients achieved a postoperative binocular UDVA, UIVA, and UNVA of 20/25 or better, respectively. Likewise, 100%, 80%, and 84% of patients achieved a postoperative binocular CDVA, DCIVA, and DCNVA of 20/25 or better, respectively. In the defocus curve, all mean visual acuity values were better than 0.15 logMAR for all defocus levels. A total of 95.8%, 95.8%, and 91.7% of patients referred to be satisfied with their distance, intermediate, and near visual vision, respectively. Mean overall Catquest Rasch calibrated score was −3.12 ± 0.98. Most of the patients were spectacle independent: far (95.8%), intermediate (95.8%) or near vision (91.7%). No bothersome or minimal to moderately bothersome halo, starburst, and glare was perceived by 83.3%, 83.4%, and 83.3% of patients, respectively. Conclusions: The trifocal IOL evaluated provides a visual acuity improvement, with high levels of spectacle independence, patient satisfaction, and perceived visual quality associated.

Background/Objectives: To objectively evaluate the rotational stability, refractive predictability, and visual outcomes of toric EVO ICL using automated infrared retinal retroillumination imaging. Setting/Venue: The research was conducted in a specialized ophthalmic surgery center. Design: Longitudinal analytical prospective study. Methods: The methodology included preoperative and postoperative assessments of visual acuity, subjective refraction, corneal topography, and anterior segment OCT. The implantation and alignment process utilized advanced digital centration techniques. Postoperative evaluations were conducted at 1 and 3. Results: The study found a mean incision surgically induced astigmatism (SIA) of 0.32 D, and a refractive SIA average of 2.02 D, closely matching the preoperative refractive astigmatism (target-induced astigmatism—TIA) mean of 2.07 D, resulting in a correction index (CI) of 0.96. Rotational stability was high, with 72% of lenses showing less than 5° rotation and 96% under 10° at the 1-month follow-up. No significant correlations were observed between lens rotation and postoperative vault size or horizontal compression, indicating independent factors. The discrepancy between theoretical and observed rotations suggested that the calculation method slightly underestimated actual rotation, which did not significantly affect visual outcomes. Graphical analysis demonstrated minimal impact of lens rotation on uncorrected distance visual acuity (UDVA), confirming the procedure’s efficacy and safety. Conclusions: Toric EVO ICL implants provide high rotational stability, excellent refractive predictability, and satisfactory visual outcomes. The study underscores the importance of precise implantation and the minimal influence of lens rotation on postoperative refractive errors.

Objectives: To evaluate the clinical performance and optical quality of a non-diffractive extended-depth-of-focus (EDOF) intraocular lens (IOL), Asqelio™ EDOF (models ETLIO130C/ETPIO130C), in patients undergoing cataract surgery or refractive lensectomy. Methods: This prospective observational, case-control study included patients bilaterally implanted with either the Asqelio™ EDOF IOL (Study Group) or the spherical monofocal TECNIS^® 1-Piece ZCB00 IOL (Control Group). The postoperative outcomes—at 3 months after surgery—included visual acuities at multiple distances, refraction, contrast sensitivity, the optical scatter index (OSI), wavefront aberrations, and patient-reported outcomes (Catquest-9SF and a quality-of-vision questionnaire). Results: Twenty-three patients (46 eyes) in the Asqelio™ EDOF group and 17 patients (34 eyes) in the monofocal control group were enrolled. Postoperatively, 91% of eyes in the EDOF group were within ±0.50 D of the intended spherical equivalent. The binocular uncorrected distance, intermediate, and near visual acuities were 0.00 ± 0.09, 0.13 ± 0.12, and 0.32 ± 0.15 logMAR, respectively. Contrast sensitivity and OSI values were similar between the study and control groups (p > 0.05). Higher-order aberrations were significantly lower in the EDOF group (p < 0.001), but values in both groups were clinically low. No adverse events were reported. Most patients expressed high satisfaction and reported few visual disturbances. Conclusions: The Asqelio™ EDOF IOL provided good refractive predictability, effective uncorrected vision across distance and intermediate ranges, and high patient satisfaction. Contrast sensitivity and optical scatter were comparable to monofocal implants. This lens can be considered a valuable option for patients seeking an extended range of functional vision with minimal side effects.

Purpose: We synthesized the current evidence on isotretinoin-induced Meibomian gland dysfunction (MGD), including underlying mechanisms, clinical manifestations, risk factors, management strategies, and the need for updated screening recommendations. Methods: The review was conducted during November 2025, covering multiple databases including Semantic Scholar, PubMed, and others. The search yielded 1,046 records; after eligibility assessment, 53 studies were included. Clinical, preclinical, and review articles, as well as clinical guidelines were considered if they met predefined quality standards. Results: Isotretinoin significantly impairs Meibomian gland function by suppressing PPARγ signalling, leading to reduced lipid secretion, glandular inflammation, and atrophy. These effects often precede overt symptoms, complicating early diagnosis. Risk factors include prolonged or high-dose therapy, pre-existing ocular surface disease, contact lens wear, and dermatologic or systemic comorbidities. Clinical manifestations range from mild dry eye symptoms to persistent ocular surface damage. Current management is largely palliative, and there is no validated therapy for reversing gland atrophy. Despite mounting evidence, existing clinical guidelines do not recommend ophthalmologic screening, potentially delaying diagnosis and intervention. Conclusion: Isotretinoin-induced MGD is a clinically significant and underrecognized adverse effect. The absence of routine ophthalmological screening and standardized monitoring protocols leaves high-risk patients vulnerable to irreversible gland damage. Proactive surveillance, structured prevention, and individualized management are essential to minimize long-term ocular complications. Among all strategies, infrared meibography may serve as an objective, non-invasive tool to monitor isotretinoin-induced Meibomian gland damage, guiding early intervention and treatment decisions. Further research is needed to establish optimal screening strategies and explore effective preventive and restorative therapies.